Comparison of Outcomes of Donor Lymphocyte Infusions With or Without Lenalidomide in Patients with Hematological Malignancies Post Allogeneic HSCT

Outcomes with DLI alone for post-transplant relapsed hematological malignancies are poor especially in acute leukemias. Addition of immunomodulatory drugs to DLI may augment GVL effect. Use of lenalidomide with DLI to augment GVL has not been previously reported. This retrospective analysis was to c...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Indian journal of hematology & blood transfusion 2023-01, Vol.39 (1), p.40-49
Hauptverfasser:	Punatar, Sachin, Murugaiyan, Vinodhini, Kumbhalwar, Komal, Gokarn, Anant, Chichra, Akanksha, Mirgh, Sumeet, Nayak, Lingaraj, Bonda, Avinash, Jindal, Nishant, Shirure, Vijay, Bagal, Bhausaheb, Mathew, Libin, Kannan, Sadhana, Saikia, Tapan, Khattry, Navin
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood & organ donations Blood cancer Blood Transfusion Medicine Clinical outcomes Hematology Human Genetics Immunotherapy Lymphocytes Medicine Medicine & Public Health Oncology Original Original Article Stem cell transplantation Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!